10-Q: Axogen Reports 17.4% Revenue Increase in Q1 2025, Progresses Towards BLA Approval

Axogen, Inc. announces a 17.4% increase in revenue for the first quarter of 2025 and highlights progress in its Biologics License Application (BLA) for Avance Nerve Graft.

Summary

• Axogen, Inc. reported revenues of $48.56 million for the quarter ended March 31, 2025, representing a 17.4% increase compared to the $41.38 million reported for the same period in 2024.
• The revenue increase was driven by a 12.0% increase in unit volume and a combined 5.3% increase from changes in price and product mix.
• Gross profit for the quarter increased by 7.1% to $34.93 million, compared to $32.62 million in the prior year.
• Gross margin decreased to 71.9% from 78.8% due to lower margins on products sold and increased inventory write-offs.
• The company's net loss decreased to $3.83 million, or $0.08 per share, compared to a net loss of $6.64 million, or $0.15 per share, for the same quarter last year.
• The FDA accepted the filing of the company's BLA for Avance Nerve Graft on November 1, 2024, with a PDUFA goal date of September 5, 2025.
• Axogen completed several regulatory milestones in Q1 2025, including a mid-cycle meeting with the FDA, clinical trial site inspections, and a sponsor inspection under the FDA's Bioresearch Monitoring program.
• The company believes its existing cash, cash equivalents, and investments, along with sales revenue, will fund operations for at least the next twelve months.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and a reduced net loss. However, the gross margin decline and macroeconomic risks temper the overall sentiment.

Positives

• Revenue increased by 17.4% year-over-year, indicating strong sales performance.
• Net loss decreased significantly, suggesting improved operational efficiency.
• The FDA accepted the BLA filing for Avance Nerve Graft, and the company is progressing through the regulatory process.
• The company believes it has sufficient liquidity to fund operations for the next twelve months.
• The company's current ratio is 4.3x, indicating strong liquidity.

Negatives

• Gross margin decreased from 78.8% to 71.9%, driven by higher product costs and increased inventory write-offs.
• Cash and cash equivalents decreased by $9.46 million during the quarter.
• The company is continuing discussions with grant authorities regarding the evaluation, expiration and clawbacks of the job creation milestones and expects to receive a response during 2025.
• The company could be obligated to pay back up to approximately $950 as of March 31, 2025 related to economic development grants.

Risks

• The company is subject to risks and exposures from the evolving macroeconomic environment, including financial market volatility, geopolitical tensions and escalating trade disputes with U.S. trading partners.
• The company is dependent on its processing facilities at its Axogen Processing Center (APC Facility) in Vandalia, Ohio and the facility it leases from Solvita in Dayton, Ohio.
• The company could be obligated to pay back up to approximately $950 as of March 31, 2025 related to economic development grants.
• The company has become aware that the Lender may have an alternative interpretation of the calculation of the make-whole payments that the Company believes does not properly utilize the same methodology utilized by the XIRR function in Microsoft Excel as described in the Credit Facility.

Future Outlook

The company believes its existing cash, cash equivalents, and investments, along with sales revenue, will be sufficient to fund operations for at least the next twelve months.

Management Comments

• We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries.
• Our strategy remains focused on deepening our presence in high-potential accounts, specifically Level 1 trauma centers and academic-affiliated hospitals with a high number of trained microsurgeons.
• We will drive growth in these accounts through targeted expansion of nerve repair indications and driving deeper adoption of our nerve repair algorithm across multiple surgical specialties.

Industry Context

Axogen operates in the peripheral nerve repair market, which is driven by the increasing incidence of nerve injuries and the growing demand for effective treatment options. The company's focus on high-potential accounts and expansion of nerve repair indications aligns with industry trends.

Comparison to Industry Standards

• It is difficult to compare Axogen's results directly to industry standards without specific competitor data.
• However, medical device companies like Stryker, Medtronic, and Johnson & Johnson operate in broader markets and have different growth profiles.
• Axogen's 17.4% revenue growth suggests a strong position in its niche market, but its gross margin decline warrants attention compared to industry benchmarks.

Legal Proceedings

• The Company is and may be subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business.

Stakeholder Impact

• Shareholders: The increased revenue and reduced net loss are positive for shareholders.
• Employees: Stock-based compensation plans are in place for employees.
• Customers: The company continues to provide innovative nerve repair solutions.
• Suppliers: The company has distribution and supply agreements in place.

Next Steps

• The company anticipates potential approval of the Avance Nerve Graft BLA on September 5, 2025.
• The company will continue discussions with grant authorities regarding the evaluation, expiration and clawbacks of the job creation milestones and expects to receive a response during 2025.
• The company will continue to focus on deepening its presence in high-potential accounts and expanding nerve repair indications.

Key Dates

Keywords

Axogen, nerve repair, Avance Nerve Graft, BLA, revenue, gross profit, net loss, FDA, financial results, peripheral nerve